Oric Pharmaceuticals, Inc. — Investor Relations & Filings
Filings indexed
390
across all filing types
Latest filing
2026-04-28
Proxy Solicitation & In…
Country
US
United States of America
Listing
US
ORIC
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer. The company's platform addresses the primary mechanisms of therapeutic resistance—innate, acquired, and bypass—with the goal of making existing treatments more effective and durable. Its pipeline includes several targeted therapeutics in clinical development. Key programs include enozertinib (ORIC-114), an inhibitor being studied in non-small cell lung cancer (NSCLC) with specific EGFR/HER2 mutations, and ORIC-944, which is in trials for prostate cancer. Oric employs a precision oncology approach, using biomarkers to identify patient populations most likely to respond to its treatments.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEF 14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer) | 2026-04-28 | English | |
| 4 - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-26 | English | |
| 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | |
| 10-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | |
| 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 38155746 | DEF 14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer) | 2026-04-28 | English | ||
| 32898467 | 4 - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-26 | English | ||
| 32898472 | 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | ||
| 32898475 | 10-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | ||
| 32898468 | 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | ||
| 31755143 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 13223467 | Major Shareholding Notification 2026 | 2026-01-21 | English | ||
| 13223468 | Director's Dealing 2026 | 2026-01-21 | English | ||
| 13223469 | Regulatory Filings 2026 | 2026-01-16 | English | ||
| 13223470 | Regulatory Filings 2026 | 2026-01-16 | English | ||
| 13223471 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223472 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223473 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223474 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223475 | Director's Dealing 2026 | 2026-01-06 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Oric Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32131/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32131 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32131 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32131 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32131}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Oric Pharmaceuticals, Inc. (id: 32131)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.